Non-Muscle Invasive Bladder Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen Research

Posted on
by

Non-Muscle Invasive Bladder Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen Research
The Non-Muscle Invasive Bladder Cancer Market Forecast report offers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the 7MM.

DelveInsight’s “Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Non-Muscle Invasive Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Muscle Invasive Bladder Cancer Market Forecast

 

Some of the key facts of the Non-Muscle Invasive Bladder Cancer Market Report: 

  • The Non-Muscle Invasive Bladder Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In December 2023, CG Oncology revealed that the US FDA has awarded both Fast Track Designation (FTD) and Breakthrough Therapy Designation (BTD) for cretostimogene grenadenorepvec in high-risk BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ, whether accompanied by Ta or T1 (papillary) tumors or not.
  • In December 2023, Johnson & Johnson declared that the US FDA has awarded Breakthrough Therapy Designation (BTD) to TAR-200 for the possible future therapy of patients with BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), who are not suitable for or have chosen not to undergo radical cystectomy.
  • In the seven major markets (7MM), the United States recorded the highest number of cases in 2023, totaling approximately 600,000 prevalent cases. It is anticipated that these cases will continue to rise throughout the forecast period.
  • As per the projections, in Japan, NMIBC was most commonly found in the age group of 70-89, constituting roughly 60% of the total cases observed in 2023.
  • According to DelveInsight’s projections, approximately 600,000 prevalent cases of NMIBC were reported in the US in 2023.
  • As indicated by the American Urological Association and European Association of Urology, Non-Muscle Invasive Bladder Cancer (NMIBC) constitutes around 75% of all bladder cancer cases.
  • As per Valenza et al. (2022), approximately 20–40% of patients experience disease recurrences or persistence after undergoing BCG treatment, leading to their classification as BCG unresponsive.
  • Key Non-Muscle Invasive Bladder Cancer Companies: CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others
  • Key Non-Muscle Invasive Bladder Cancer Therapies: CG0070, Sasanlimab (PF-06801591), UGN-102 (mitomycin), TAR-200, TARA-002, OH2 injection, STM-416, Durvalumab, BCG+N-803, Cabazitaxel, Cetrelimab, TL-532, AU-011, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Nivolumab, APL-1202, and others
  • The Non-Muscle Invasive Bladder Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Muscle Invasive Bladder Cancer pipeline products will significantly revolutionize the Non-Muscle Invasive Bladder Cancer market dynamics.

 

Non-Muscle Invasive Bladder Cancer Overview

Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer that starts in the innermost lining of the bladder (urothelium) and has not spread beyond the muscular layer of the bladder wall. It typically involves the superficial layers of the bladder lining and does not invade the deeper muscle layers. NMIBC includes two main types: carcinoma in situ (CIS) and papillary tumors (Ta or T1). 

 

Get a Free sample for the Non-Muscle Invasive Bladder Cancer Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market

 

Non-Muscle Invasive Bladder Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-Muscle Invasive Bladder Cancer Epidemiology Segmentation:

The Non-Muscle Invasive Bladder Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Non-Muscle Invasive Bladder Cancer
  • Prevalent Cases of Non-Muscle Invasive Bladder Cancer by severity
  • Gender-specific Prevalence of Non-Muscle Invasive Bladder Cancer
  • Diagnosed Cases of Episodic and Chronic Non-Muscle Invasive Bladder Cancer

 

Download the report to understand which factors are driving Non-Muscle Invasive Bladder Cancer epidemiology trends @ Non-Muscle Invasive Bladder Cancer Epidemiology Forecast

 

Non-Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to get launched during the study period. The analysis covers Non-Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Muscle Invasive Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-Muscle Invasive Bladder Cancer Therapies and Key Companies

  • CG0070: CG Oncology
  • Sasanlimab (PF-06801591): Pfizer
  • UGN-102 (mitomycin): UroGen Pharma
  • TAR-200: Janssen Research & Development, LLC
  • TARA-002: Protara Therapeutics
  • OH2 injection: Binhui Biopharmaceutical
  • STM-416: SURGE Therapeutics
  • Durvalumab: AstraZeneca
  • BCG+N-803: ImmunityBio, Inc.
  • Cabazitaxel: Guarionex J. Decastro
  • Cetrelimab: Janssen Research & Development
  • TL-532: Tollys
  • AU-011: Aura Biosciences
  • VAX 014: Vaxiion Therapeutics
  • Pemigatinib: Incyte Corporation
  • Erdafitinib: Janssen Pharmaceuticals
  • TLD 1433: Theralase Technologies
  • Nivolumab: BristolMyers Squibb
  • APL-1202: Asieris Pharmaceuticals

 

Discover more about therapies set to grab major Non-Muscle Invasive Bladder Cancer market share @ Non-Muscle Invasive Bladder Cancer Treatment Landscape 

 

Non-Muscle Invasive Bladder Cancer Market Strengths

  • Potent ICI-based gene therapies can alter the disease trajectory, halting its advancement to advanced stages—an impactful stride in managing NMIBC. Their potential to fulfill approval criteria further underscores their pivotal role in advancing NMIBC treatment.
  • Sasanlimab’s ease of subcutaneous administration and compelling clinical effectiveness position it as a standout candidate in the evolving field of cancer immunotherapy.

 

Non-Muscle Invasive Bladder Cancer Market Opportunities

  • The growing focus on research and development to introduce biomarkers for improved diagnosis and the exploration of combination therapy with BCG presents a promising opportunity in the NMIBC market.
  • The emergence of innovative treatments like CG0070, N-803, non-viral plasmid based therapy, and others signifies a promising advancement in NMIBC treatment. These therapies offer targeted and innovative approaches to address cancer.

 

Scope of the Non-Muscle Invasive Bladder Cancer Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Non-Muscle Invasive Bladder Cancer Companies: CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others
  • Key Non-Muscle Invasive Bladder Cancer Therapies: CG0070, Sasanlimab (PF-06801591), UGN-102 (mitomycin), TAR-200, TARA-002, OH2 injection, STM-416, Durvalumab, BCG+N-803, Cabazitaxel, Cetrelimab, TL-532, AU-011, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Nivolumab, APL-1202, and others
  • Non-Muscle Invasive Bladder Cancer Therapeutic Assessment: Non-Muscle Invasive Bladder Cancer current marketed and Non-Muscle Invasive Bladder Cancer emerging therapies
  • Non-Muscle Invasive Bladder Cancer Market Dynamics: Non-Muscle Invasive Bladder Cancer market drivers and Non-Muscle Invasive Bladder Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Non-Muscle Invasive Bladder Cancer Unmet Needs, KOL’s views, Analyst’s views, Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement 

 

To know more about Non-Muscle Invasive Bladder Cancer companies working in the treatment market, visit @ Non-Muscle Invasive Bladder Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Non-Muscle Invasive Bladder Cancer Market Report Introduction

2. Executive Summary for Non-Muscle Invasive Bladder Cancer

3. SWOT analysis of Non-Muscle Invasive Bladder Cancer

4. Non-Muscle Invasive Bladder Cancer Patient Share (%) Overview at a Glance

5. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance

6. Non-Muscle Invasive Bladder Cancer Disease Background and Overview

7. Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Muscle Invasive Bladder Cancer 

9. Non-Muscle Invasive Bladder Cancer Current Treatment and Medical Practices

10. Non-Muscle Invasive Bladder Cancer Unmet Needs

11. Non-Muscle Invasive Bladder Cancer Emerging Therapies

12. Non-Muscle Invasive Bladder Cancer Market Outlook

13. Country-Wise Non-Muscle Invasive Bladder Cancer Market Analysis (2020–2034)

14. Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement of Therapies

15. Non-Muscle Invasive Bladder Cancer Market Drivers

16. Non-Muscle Invasive Bladder Cancer Market Barriers

17.  Non-Muscle Invasive Bladder Cancer Appendix

18. Non-Muscle Invasive Bladder Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/